New
HealthMore in Health →
Incyte Moves Toward a Vitiligo Filing After Twin Phase 3 Successes
Incyte says its JAK1 inhibitor povorcitinib met goals in twin Phase 3 trials in nonsegmental vitiligo, setting up a regulatory filing and putting fresh attention on the autoimmune skin disorder market.
Key Takeaways
- Incyte says povorcitinib succeeded in twin Phase 3 vitiligo trials.
- The company plans to seek approval in nonsegmental vitiligo.
DE
DT Editorial AI··via endpoints.news